🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06894277
Recruiting Not applicable

An Interactive Education Program to Reduce High Risk Behavior in Adolescents Ph II (iTRAC HERO)

NCT06894277 · tracked via the Priya Life Science USA tracker
Sponsor
Klein Buendel, Inc.
Phase
Not applicable
Started
2025-04-01
Last updated
2026-06-16

Condition(s) studied

Risky Sexual BehaviorEmotion RegulationAdolescent Behavior

Investigational drug(s) / intervention(s)

iTRAC-HERO

iTRAC-HERO: iTRAC-HERO will consist of eight, approximately 45-minute, "gamified" digital modules of 4-6 activities (games, videos, etc.). No instruction is needed to use the program. Content will use gender- and sexuality-inclusive language and avoid heteronormative descriptions of risk. This content will include strategies for (and practice with) recognizing and managing emotions, particularly in relation to sexual health situations, to enhance the likelihood that the emotion regulation and sexual health education provided can be applied to experiences that are emotionally arousing and lead to risk.

Study summary

Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will create and test iTRAC-HERO to teach emotion regulation skills in the context of sexual health education.

Eligibility

Sex
ALL
Min age
12 Years
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: * Attending 7th grade * Between 12 and 14 years old * Parent/guardian speaks English or Spanish * Attending participating school Exclusion Criteria: * Unable to read at a 4th grade level * Have a sibling who has participated in the study * Have a development disorder

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Klein Buendel, Inc. Golden Colorado Recruiting

More Klein Buendel, Inc. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06894277 on ClinicalTrials.gov ↗ ← All trials in the USA